Previous 10 | Next 10 |
2023-05-11 17:15:57 ET Regulus Therapeutics press release ( NASDAQ: RGLS ): Q1 GAAP EPS of -$0.42 beats by $0.02 . As of March 31, 2023, Regulus had $30.3 million in cash and cash equivalents. Combined with the $15.0 million private placement in April, the Company expe...
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates PR Newswire Enrollment completed in first cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 C...
2023-04-13 08:31:05 ET Regulus Therapeutics ( NASDAQ: RGLS ) enters securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The financing was led by the Federated Hermes Kaufmann Funds and ...
Regulus Therapeutics Announces $15 Million Private Placement of Equity PR Newswire SAN DIEGO , April 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicine...
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , April 12, 2023...
2023-03-23 16:33:26 ET Regulus Therapeutics press release ( NASDAQ: RGLS ): Q4 GAAP EPS of -$0.40 beats by $0.11 . Cash, Cash Equivalents and Marketable Securities: As of December 31, 2022, Regulus had $39.2 million in cash, cash equivalents and short-term investm...
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates PR Newswire Enrollment progressing in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) T...
Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference PR Newswire SAN DIEGO , Feb. 9, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innov...
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , Jan. 13, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medici...
Regulus Therapeutics Announces Resignation of Board Member PR Newswire SAN DIEGO , Dec. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc . ( Nasdaq : RGLS ), a biopharmaceutical company focused on the discovery and development of innovative med...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...